GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024

GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024

GenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ® and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 million

GenSight Biologics Announces Preliminary Assay Indicating Successful Manufacture of Second LUMEVOQ® GMP Batch

GenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ®

GenSight Biologics Announces Successful Manufacture of LUMEVOQ® GMP Batch

GenSight Biologics Withdraws its EMA Application for LUMEVOQ®

GenSight Biologics to Host a Webcast on April 5, 2023, to Provide an Update on LUMEVOQ® Manufacturing Following Investigations Findings

GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023